NeRRe Therapeutics is developing orvepitant, a neurokinin (NK)-1 receptor antagonist, as a first in class, once daily breakthrough treatment for cough hypersensitivity disorders. Having demonstrated proof of efficacy in patients with refractory or unexplained cough, NeRRe will now continue development in chronic cough caused by the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF). A dominant feature of this severe progressive respiratory disease in a high proportion of patients is an uncontrolled and persistent cough which is disabling for these terminally ill patients. The cough is often refractory to medical therapy and there are no approved treatments. Idiopathic pulmonary fibrosis has been designated an orphan disease in both Europe and the USA.
View Top Employees from NeRRe Therapeutics LtdWebsite | http://nerretherapeutics.com |
Revenue | $5 million |
Funding | $36.3 million |
Employees | 10 (9 on RocketReach) |
Founded | 2012 |
Phone | +44 1438 906960 |
Technologies |
JavaScript,
HTML,
PHP
+7 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Manufacturing General, Manufacturing, Science and Engineering, Drug Discovery, Health Care, Medical |
Web Rank | 17 Million |
Keywords | Nerre |
Competitors | Depomed, Inc., Endocyte, Heron Therapeutics, Inc., Relypsa, TESARO, Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular NeRRe Therapeutics Ltd employee's phone or email?
The NeRRe Therapeutics Ltd annual revenue was $5 million in 2024.
Mike Trower is the Co-Founder and Chief Scientific Officer of NeRRe Therapeutics Ltd.
9 people are employed at NeRRe Therapeutics Ltd.
The NAICS codes for NeRRe Therapeutics Ltd are [32541, 32, 325, 3254].
The SIC codes for NeRRe Therapeutics Ltd are [28, 283].